MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.28M | $14.02M | $15.92M | $37.70M | $15.56M | $13.29M | N/A | N/A |
| Cost of Revenue | $23.79M | N/A | N/A | N/A | N/A | N/A | $2.05M | $679.18K |
| Gross Profit | $9.49M | $14.02M | $15.92M | $37.70M | $15.56M | $13.29M | $-2.05M | $-679.18K |
| Gross Margin | 28.51% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Operating Expenses | $173.70M | $151.08M | $132.28M | $110.46M | $78.12M | $71.56M | $76.05M | $31.01M |
| Operating Income | $-164.21M | $-137.06M | $-116.36M | $-72.76M | $-62.55M | $-58.27M | $-78.10M | $-31.68M |
| Operating Margin | -493.44% | -977.82% | -730.87% | -192.99% | -401.94% | -438.37% | 0.00% | 0.00% |
| Net Income | $-147.79M | $-84.03M | $-129.62M | $-79.56M | $-57.99M | $-54.75M | $-82.87M | $-31.04M |
| Net Margin | -444.10% | -599.46% | -814.16% | -211.03% | -372.63% | -411.87% | 0.00% | 0.00% |
| EPS (Basic) | $-2.12 | $-1.49 | $-3.16 | $-1.63 | $-1.43 | $-1.58 | $-4.37 | $-3.62 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |